1. Home
  2. IMRN vs GRNQ Comparison

IMRN vs GRNQ Comparison

Compare IMRN & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • GRNQ
  • Stock Information
  • Founded
  • IMRN 1994
  • GRNQ 2013
  • Country
  • IMRN Australia
  • GRNQ Malaysia
  • Employees
  • IMRN N/A
  • GRNQ N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • IMRN Health Care
  • GRNQ Technology
  • Exchange
  • IMRN Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • IMRN 9.2M
  • GRNQ 10.6M
  • IPO Year
  • IMRN N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • IMRN $1.80
  • GRNQ $1.40
  • Analyst Decision
  • IMRN Strong Buy
  • GRNQ
  • Analyst Count
  • IMRN 1
  • GRNQ 0
  • Target Price
  • IMRN $5.00
  • GRNQ N/A
  • AVG Volume (30 Days)
  • IMRN 46.0K
  • GRNQ 23.6K
  • Earning Date
  • IMRN 08-29-2025
  • GRNQ 11-12-2025
  • Dividend Yield
  • IMRN N/A
  • GRNQ N/A
  • EPS Growth
  • IMRN N/A
  • GRNQ N/A
  • EPS
  • IMRN N/A
  • GRNQ N/A
  • Revenue
  • IMRN $4,777,422.00
  • GRNQ $3,256,679.00
  • Revenue This Year
  • IMRN N/A
  • GRNQ N/A
  • Revenue Next Year
  • IMRN N/A
  • GRNQ N/A
  • P/E Ratio
  • IMRN N/A
  • GRNQ N/A
  • Revenue Growth
  • IMRN 48.63
  • GRNQ N/A
  • 52 Week Low
  • IMRN $1.50
  • GRNQ $0.80
  • 52 Week High
  • IMRN $2.87
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 48.13
  • GRNQ 47.44
  • Support Level
  • IMRN $1.80
  • GRNQ $1.37
  • Resistance Level
  • IMRN $1.94
  • GRNQ $1.51
  • Average True Range (ATR)
  • IMRN 0.08
  • GRNQ 0.10
  • MACD
  • IMRN -0.01
  • GRNQ 0.02
  • Stochastic Oscillator
  • IMRN 22.22
  • GRNQ 61.29

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: